Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
In brief
JNJ's collaboration with Sail Biomedicines could lead to significant advancements in autoimmune disease treatment and potentially impact the company's earnings in 2026 and 2027.